Ratings for Hims & Hers Health HIMS were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 1 | 3 | 1 | 0 |
| Last 30D | 1 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 1 | 0 |
| 3M Ago | 3 | 0 | 2 | 0 | 0 |
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $27.75, accompanied by a high estimate of $42.00 and a low estimate of $18.00. This current average reflects an increase of 13.03% from the previous average price target of $24.55.
Breaking Down Analyst Ratings: A Detailed Examination
An in-depth analysis of recent analyst actions unveils how financial experts perceive Hims & Hers Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $24.00 | $21.00 |
| Ryan MacDonald | Needham | Raises | Buy | $31.00 | $28.00 |
| Craig Hettenbach | Morgan Stanley | Announces | Overweight | $42.00 | - |
| Maria Ripps | Canaccord Genuity | Raises | Buy | $38.00 | $28.00 |
| Jonna Kim | TD Cowen | Maintains | Buy | $28.00 | $28.00 |
| Allen Lutz | B of A Securities | Lowers | Underperform | $18.00 | $32.00 |
| Jonna Kim | TD Cowen | Raises | Buy | $28.00 | $25.00 |
| George Hill | Deutsche Bank | Raises | Hold | $27.00 | $23.00 |
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $21.00 | $18.00 |
| Maria Ripps | Canaccord Genuity | Raises | Buy | $28.00 | $24.00 |
| Michael Cherny | B of A Securities | Raises | Buy | $25.00 | $23.00 |
| Michael Cherny | B of A Securities | Raises | Buy | $23.00 | $20.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Hims & Hers Health's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hims & Hers Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
All You Need to Know About Hims & Hers Health
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Understanding the Numbers: Hims & Hers Health's Finances
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Hims & Hers Health's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 77.13%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's net margin is impressive, surpassing industry averages. With a net margin of 18.82%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Hims & Hers Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.85% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hims & Hers Health's ROA stands out, surpassing industry averages. With an impressive ROA of 13.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Hims & Hers Health's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
